Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference by Giorgi Rossi, Paolo et al.
Preventive Medicine 98 (2017) 21–30
Contents lists available at ScienceDirect
Preventive Medicine
j ourna l homepage: www.e lsev ie r .com/ locate /ypmedCervical cancer screening in women vaccinated against human
papillomavirus infection: Recommendations from a
consensus conferencePaolo Giorgi Rossi a,b, Francesca Carozzi c,⁎, Antonio Federici d, Guglielmo Ronco e, Marco Zappa f,
Silvia Franceschi g, The Italian Screening in HPV vaccinated girls Consensus Conference group 1:
a Epidemiology Unit, Azienda Unità Sanitaria Locale, Via Amendola 2, 42122, Reggio Emilia, Italy
b Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico - IRCCS, Reggio Emilia, Italy
c Cancer Prevention Regional Laboratory, ISPO, Cancer Prevention and Research Institute, Florence, Italy
d Italian Ministry of Health, Rome, Italy
e Center for Cancer Epidemiology and Prevention, AO City of Health and Science, Turin, Italy
f Unit of Clinical and Descriptive Epidemiology, ISPO, Florence, Italy
g International Agency for Research on Cancer, 69372 Lyon Cedex 08, FranceAbbreviations: AIRTUM, Italian Association of Cancer R
Intraepithelial Neoplasia; DNA, Deoxyribonucleic acid; GI
International Agency for Research on Cancer; ICO, Catala
Monitoring Centre; PASSI, “Progressi dell'Aziende Sani
Diagnostic Cytology; SICi, Italian Society of Cytology; SIC
Italian Society of Hygiene, Preventive medicine and Public
⁎ Corresponding author at: Cancer Prevention Regional
E-mail addresses: paolo.giorgirossi@ausl.re.it (P. Giorg
m.zappa@ispo.toscana.it (M. Zappa), franceschis@iarc.fr (
1 Group members: Alessandra Barca, Roma; Luisa Barz
Franco Maria Buonaguro, Napoli; Elena Burroni, Firenze,
Palma, Trento; Silvia Declich, Roma; Annarosa Del Mistr
Giambi, Roma; Stefania Iannazzo, Roma; Anna Iossa, Fir
Roma; Carlo Naldoni, Bologna; Cristina Ocello, Firenze; Eu
Cagliari; Antonio Placidi, Roma; Maria Grazia Pompa, Rom
Roma; Nereo Segnan, Torino; Mario Sideri, Milano; Ars
Vocaturo, Roma; Manuel Zorzi, Padova
http://dx.doi.org/10.1016/j.ypmed.2016.11.020
0091-7435/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 4 November 2016
Received in revised form 14 November 2016
Accepted 24 November 2016
Available online 25 November 2016In Italy, the cohorts of womenwhowere offered Human papillomavirus (HPV) vaccination in 2007/08will reach
the age (25 years) for cervical cancer (CC) screening from 2017. The simultaneous shift from cytology-based
screening to HPV test-based screening gives the opportunity for unprecedented reorganisation of CC prevention.
The ONS (National Screening Monitoring Centre) Directive and the GISCi (Italian Group for Cervical Screening)
identified the consensus conference as themost suitablemethod for addressing this topic. A summary of consen-
sus recommendations is reported here. Themain objective was to define the best screeningmethods in girls vac-
cinated against HPV and the knowledge required for defining evidence-based screening strategies. A Jury made
recommendations about questions and proposals formulated by a panel of experts representative of Italian sci-
entific societies involved in CC prevention and based on systematic reviews of literature and evidence. The Jury
considered changing the screening protocols for girls vaccinated in their twelfth year as appropriate. Tailored
screening protocols based on vaccination status could be replaced by “one size fits all” protocols only when a
herd immunity effect has been reached. Vaccinated women should start screening at age 30, instead of 25,
withHPV test. Furthermore, there is a strong rationale for applying longer intervals for re-screeningHPVnegative
women than the currently recommended 5 years, but research is needed to determine the optimal screening
time points. For non-vaccinated women and for women vaccinated in their fifteenth year or later, the current
protocol should be kept.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Human papillomavirus (HPV) vaccination will be reaching the age for
screening for the precursors of invasive cervical cancer (ICC). This hap-
pens while screening is moving from being cytology-based to HPV-
based. This situation represents a challenge but also an opportunity
for unprecedented reorganisation of CC prevention (WHO/RHR, 2006).
In Italy, organised vaccination and cervical screening are managed
byRegions, according to national prevention and vaccination plans. Cur-
rent national screening guidelines recommend invitation for cytology-
based screening every 3 years from age 25 to 30–35 years and for
HPV-based screening every 5 years thereafter up to age 64. According
to the national vaccination strategy, girls are invited for HPV vaccination
during their 12th year of age. This strategy started in 2008, inviting the
cohort of women born in 1996, who will reach 25 years - the age for
being invited for screening - in 2021. In addition, some Regions adopted
a multi-cohort vaccination strategy, vaccinating adolescents in their
16th or 18th year. The first of them are reaching 25 years in 2016,
most will in 2018 (Giambi, 2014). Further details on the implementa-
tion of both programs are provided in Results (Question 1).
This new situation means that organised screening programs must
review their strategies. In this context, providing regional decision
makers (as it happened for HPV-based screening) with clear, practical
and feasible national information, based on the best scientific evidence
and defined with the participation of professional involved in the sub-
ject, is fundamental in order to standardise procedures throughout the
country. Indeed, concerning HPV-based screening, a Health Technology
Assessment report was published in 2012 on the basis of a systematic
literature review about efficacy and undesired effects, conducted also
in the frame of the preparation of EU guidelines (Ronco et al., 2012). It
advisedmoving toHPV-based screening- and provided a detailed proto-
col. The national Ministry of Health (MOH) endorsed such conclusions
in 2013. After direct evidence of greater efficacy of HPV-based screening
in preventing ICC, (Ronco et al., 2014) the 2014 National PreventionFig. 1. Contribution of the work packages to the evidence supportingPlan required a progressive shift to HPV-based screening within 2018
(AIRTUM, 2015).
A Consensus Conference was organised in 2015. Its main objective
was to define the best screening methods in girls vaccinated against
HPV and the knowledge required for defining evidence-based screening
strategies. The Consensus Conference identified and defined the central
and local actions to be implemented in order to optimise the integration
of primary prevention programs with secondary prevention programs,
as well as research activities connected with the knowledge needed
for change.
A summary is reported here (Fig. 1).
2. Materials and methods
2.1. Consensus Conference organisation
The ONS (National Screening Monitoring Centre, a governmental
agency supporting the MOH and local health authorities in screening
implementation and monitoring) Directive and the GISCi (Italian
Group for Cervical Screening, the scientific society of Italian organised
cervical screening programmes) Coordination Committee defined the
general aim and identified a Promoter Committee.
The Promoter Committee, including four technical experts fromONS
and GISCi, identified the Consensus Conference model (Supplementary
Figure), developed by the national system for guidelines (http://www.
snlg-iss.it/), as the most suitable method. The Promoter Committee
appointed a Scientific Committee (SC), including experts, and a Jury, in-
cluding experts and stakeholders.
The Technical Scientific Committee defined the objective and scope.
Then it collected and summarised available evidence. Work packages
were assigned to TSC members or to external experts, identified by
their recent research. A pre-conference document with questions (see
Table 1), proposed solutions (see Table 2) and the evidence supporting
the proposed solutions was prepared.
For each question the Jury expressed an answer, which could be:screening recommendations for the individual questions posed.
Table 2
Synthesis of the recommendations proposed by the Scientific Technical Committee and
Jury's response to the first 3 questions posed at the Consensus Conference.
Q. Proposals of the Scientific Technical
Committee
Recommendations of the Jury
1 Based on international literature, the
participants in the Consensus
Conference consider changing the
screening program protocols upon
the arrival of the vaccinated cohorts
as appropriate.
The Jury responded positively with
full consent. Tailored screening
protocols based on the vaccination
status could at some point be
replaced by one size fits all screening
protocols, when the vaccination
coverage has reached levels such that
infections from HPV16/18 (included
in the vaccines currently used) can be
considered practically negligible. The
Jury also stressed the fact that
screening activity must continue and
be performed within organised
screening programs also for
vaccinated women.
2 For girls vaccinated in their 12th year,
i.e. presumably naive, a combined
sequential strategy is proposed:
1. Tailored strategy
2. One size fits all strategy: this
method may be adopted when
local coverage reaches the thresh-
old established by the Ministry for
vaccination coverage.
The Jury approves with full consent
the proposal that invites the Regions
to link as soon as possible individual
data between lists of vaccinated
women and lists of women invited to
and/or who participated in screening,
in accordance with data protection
regulations. The Jury also
recommends that tailored protocols,
according to vaccination status, are
gradually extended to all Italian
Regions, in parallel with the
implementation and validation (for
quality and completeness) of IT
systems. The Jury agrees to consider a
uniform strategy as the final objective
of the process, believing that the
minimum level of vaccination
coverage must be carefully assessed.
This, according to the Jury, could be
well below 95%.
2.1 There is a strong rational for
proposing an increase in the starting
age for screening to 30 years for girls
vaccinated in their twelfth year.
For girls vaccinated in their 12th year
(±1 year), the Jury accepts, with full
consent, the proposal to increase the
starting age for screening to 30 years.
2.2 In girls vaccinated in their12th year,
the screening test will be the HPV
test. In the cohorts vaccinated in their
15th year or later (screening starting
at age 25) Pap testing will initially
remain.
The Jury accepts with full consent the
choice of the HPV test as the
screening test for women vaccinated
in their 12th year (suggesting
screening start at age 30). For
non-vaccinated women, in
agreement with a tailored strategy,
the current protocol must be
continued, with cytological screening
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○ Consensus for the recommendation but need for reformulation, pro-
viding relevant indications;
○ No consensus for the recommendation.
The Italian integral report is published on the ONS (www.
osservatorionazionalescreening.it) and GISCi (www.gisci.it) websites,
and has been officially presented to decision makers: the Ministry of




From the ITACAN database, the current Invasive Cervical Cancer
(ICC) incidence rates in Italy by calendar period (before and after
organised screening implementation) and by age (b25 years – age of
screening start, 25–29 and 30–35 years) were calculated (AIRTUM,
2015). An analysis of vaccination strategies in each region was per-
formed (Intesa tra il Governo le Regioni e le Provincie autonome,
2007). Vaccination coverage with 1, 2 and 3 doses, by region and birth
cohort was retrieved (Giambi, 2014; Giambi et al., 2013; Intesa tra il
Governo, le Regioni e le Province autonome di Trento e Bolzano,
2015). Screening coverage by region and age was obtained from ONS
surveys (ONS, 2015).
2.2.2. Risk of CIN3 and cancer by HPV type: main cohort studies review
A non-systematic review of the incidence of CIN3 or more severe le-
sions (CIN3+) in women positive for individual high-risk HPV (hrHPV)
types was conducted. Four cohorts about whom data of goodmethodo-
logical quality were published during the past 10 years were identified
(Khan et al., 2005; Castle et al., 2009; Kjær et al., 2010; Schiffman et al.,
2011; Thomsen et al., 2015). The outcome considered was the cumula-
tive incidence of CIN3+ at 3–5 and 10–16 years, in women positive for
HPV16, HPV18 and non-16/18 hrHPV.
2.2.3. Systematic review and pooled analysis of typing studies in Italy
The systematic review performed by the ICO HPV Information Cen-
tre, updated to 30 June 2014, was considered as methodologically
sound (Bruni et al., 2015). Starting from it 14 studies reporting ICC
genotyping in Italy were selected (Bruni et al., 2015). Only 3 of them
had published data on the proportion of types HPV 16/18 by age and
year of diagnosis (Giorgi Rossi et al., 2012a). The authors of the remain-
ing studies were contacted and 8 of them provided data, including mo-
lecular method used, histological type, presence of HPV DNA, identified
types, year of diagnosis, age at diagnosis and province of residence. The
proportion of non-HPV16/18 cancers in women aged b30 years before
organised screening started was estimated by pooling all retrievedTable 1
Questions posed by the Scientific Technical Committee to the Jury.
Consensus Conference questions
1. Do the protocols for screening programs need to be changed upon the arrival of
the cohorts of vaccinated women?
2. If so, which policy appears to be the most effectively and operatively
manageable?
o A tailored strategy;
o A one size fits all strategy.
2.1. At what age should screening start?
2.2. With which test?
2.3. How often?
3. Should the strategy be different for the cohorts vaccinated in their 15th year
(or later) with respect to those vaccinated in their 12th year?
4. Which actions need to be scheduled from now and up to 2021 in order to
acquire missing evidence and to make the integration of primary and second-
ary prevention practically possible?data. Each cancer was classified as occurring before organised screening
if at the date of incidence b50% of the target population in its area of res-
idence (province) had been invited by the local organised screeningin the 25–29 age range and HPV test
with cytology triage from age 30 to
64.
2.3 Currently there is no evidence on the
optimal intervals between rounds,
although there is a strong rational
that intervals should be longer. To
estimate ideal intervals, the data that
the screening data in girls vaccinated
in their 15th year of age or later will
be fundamental.
The Jury recognises the lack of
evidence on the optimal interval
between screening rounds in
vaccinated women, while
acknowledging the strong rational in
favour of a longer interval than
5 years, i.e. the interval currently
recommended for the HPV test in the
female population in general. It also
adheres with full consent to the
proposal to promptly start studies on
this subject.
3 Changes in screening protocols are to
be applied only to the cohorts of girls
vaccinated in their 12th year.
The Jury is favourable, with full
consent, to the recommendation not
to change current cytological
screening protocols for women
vaccinated in their 15th year or later.
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portunistic activity, which in some areas was already very widespread
prior to organised programs.
2.2.4. Model to estimate cancer incidence in different scenarios of screening
starting ages
In order to estimate the impact of increasing the starting age for
screening in vaccinated women, we estimated the incidence of
non-HPV16/18 cancers before the start of organised screening
(1990–1998) in women aged b25, b30 and b35 years (Fig. 2).
Three different estimates of the proportion of non-HPV16/18 ICC
were obtained by a pooled analysis of Italian ICC genotyping studies:
a) the raw observed proportion; b) an estimate based on a model in-
cluding age with linear effect and presence/absence of organised
screening; c) an estimate based on a model including age as categor-
ical variable (≤29, 30–34, ≥35) and presence/absence of organised
screening. Such proportions were applied to ICC incidences before
organised screening implementation in Italy (i.e. in the 1990s) and
the resulting incidences to the 2015 Italian population. The overall
ICC incidence in the same period below age 25, the starting age for
invitation to screening according to the Italian 1996 recommenda-
tions was also computed (Commissione Oncologica Nazionale,
1996). That incidence applied to the 2015 Italian population would
give 8 cases per year, which were used as reference threshold.
2.2.5. Immunogenicity duration: systematic review
A systematic review of the literature on immunogenicity and ef-
fectiveness of the vaccines against HPV was performed (Brown et
al., 2006). The target population was represented by women aged
between 19 and 44 years. The outcomes considered were: infection
from hrHPV, persistent infection (≥6 months or ≥12 months) with
hrHPV, onset of persistent lesions, CIN1+, cytological abnormalities
(ASC-US or more severe) and antibody levels IgG and/or neutralising
antibodies against HPV16 and HPV18. Studies measuring outcomes





















Fig. 2. Estimation of invasive cervical cancer incidence nation2.2.6. Cross-protection and type replacement
A non-systematic review of dynamic models on the natural history
of cervical cancer and the effect of the vaccine was performed. A narra-
tive summary of the results of models on cross-protection and type re-
placement was prepared.
2.2.7. Population effectiveness of the vaccine: systematic review
A systematic review of the literature on the effectiveness of vaccina-
tion in practice at population level was performed. The outcomes con-
sidered were: infection occurrence, cytological results, incidence or
detection rate of CIN2, CIN3, and ICC. Genital warts were considered
as indirect evidence for possible herd immunity effect. The review
started from the work of Drolet et al. (Drolet et al., 2015), updating
the research up to 8 September 2015 (Drolet et al., 2015).
2.2.8. Impact of vaccine on Pap test accuracy
A non-systematic review of literature about the impact of vaccina-
tion on the accuracy of screening tests and on the performance of
screeningwas performed. Its results were read in the light of the results
of the systematic review on the effectiveness of the vaccine at popula-
tion level.
2.2.9. Organizational impact assessment
Based on the HTA report on primary screening with HPV, the conse-
quences of vaccination and possible changes of the screening protocol
on the organisation of health services were hypothesised. Particular at-
tentionwas given to the centralisation of laboratories and the linkage be-
tween vaccination records and screeningmanagement systems (Ronco et
al., 2012). For this latter point, a feasibility analysis was performed on the
system put in place in the Lazio Region for connecting the two databases.
3. Results and discussion
The recommendations proposed by the Scientific Technical Commit-
tee and Jury's responses are reported at Tables 2 and 3. The results ofon-HPV16/18 in absence of screening.
Age
Proportion of non16-18 HPV 
Raw Model A Model B
<25 10% 15% 20%
<30 10% 15% 21%
<35 10% 11% 22%
Data from pooled analysis of Italian typing studies.
Model A includes age in classes (<30; 30-34; >=35), presence
of organised screening and typing laboratory; Model B
includes age with linear effect, presence of organised
screening and typing laboratory.
umber of non-preventable cancers in the Italian 
15 when starting screening at different ages.
Estimated Number of non-
preventable cancers 




wide in different scenarios of starting ages. (Italy; 2015).
Table 3
Recommendations proposed by the Scientific Technical Committee and the Jury's re-
sponse to the fourth question.
Proposal of the scientific technical committee approved and integrated by the jury
Recommendations for implementation
a) Link between vaccination records and screening registers. The
computerisation of vaccination records and the construction of archives at
regional and national level that are connected reciprocally and with other
databases is among the objectives of the 2014–2018 National Prevention Plan
(Objective 9.6). The link should take place at least at regional level because
girls could move around, hence changing local health administration from
where the vaccination takes place in their 12th year to where the first invita-
tion for screening at age 25 or 30 occurs.
b) Definition of a minimum set of information that the vaccination registers
must make available for screening programs;
c) Timeline definition of points a) and b);
d) Introduction of recording of CIN2+ in cancer registers and link between
vaccination registers and cancer registers; the jury recommends improving
cancer registration by recording diagnostic-therapeutic data;
e) Analysis of participation, referral for colposcopy and detection rate of high
grade CIN and ICC in screening programs for vaccinated and non-vaccinated
women;
f) Inclusion in screening archives (until vaccination record integration) of the
following data as reported by women:
i. Vaccination against HPV performed (yes/no);
ii. Number of doses;
iii. Vaccine type;
iv. Vaccination date for each dose;
Finally the Jury recommends:
Given the substantial change in screening practices, a substantial effort should be
dedicated to training healthcare operators, so that they can provide to the general
population useful and scientifically correct information on the changes to
screening practices, their efficacy, the type of test used and the starting age.
Research recommendations
g) Studies to perform:
i. Promote the conduction of studies, with a protocol shared at national level, in
order to identify conservative protocols that allow the use of the HPV testing
in women aged 25–29 years;
ii. Enrol a large cohort of vaccinated women who are HPV negative at screening.
Their detection rate of CIN3+ should be determined at subsequent screens. In
particular, for the cohorts of girls vaccinated in their 15th/16th year, if their
infection status for HPV is determined at their first screen (from 2016), such
study design can be applied for measuring the subsequent CIN3+ reduction
and defining optimal screening intervals (Fig. 3);
iii. Promote studies on the level of association between participation to screening
and to vaccination (or women's decision to vaccinate their daughters);
iv. Promote studies to assess whether the new nonavalent vaccine could change
the fundamental elements of the decision-making tree presented herein;
v. Qualitative investigations to identify tools and methods for communicating
the screening change to women and operators.
Finally the Jury recommends:
assessing the offer, the acceptance and the efficacy of the anti-HPV vaccination in
women not previously vaccinated at the start of the screening programs at age 35.
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reported hereafter.
3.1 Question 1. - Do the protocols for screening programs need to be
changed upon the arrival of the cohorts of vaccinated women?
3.1.1. Screening coverage
Organised population-based cervical screening started in Italy in the
1990ies, followingwidespread opportunistic activity. Their introduction
was followed by a significant reduction of ICC in the corresponding
areas (AIRTUM, 2015; Serraino et al., 2015; Giorgi Rossi et al., 2015). Re-
ports based on standardized process indicators are published yearly. In
2013 70% of Italian women aged 25 to 64 years (3,693,165 women) re-
ceived a letter inviting them to take part in the local cervical screening
program and 41.5% accepted (ONS, 2015).
HPV-based screening has been recommended since 2013. Women
aged 30–35 (based on regional choice) to 64 years are invited every
5 years to testing for the DNA of high-risk HPV types by validated test
as stand-alone primary test. HPV-negative women will be re-invited
in 5 years. HPV-positive women are tested by reflex cytology and re-
ferred to colposcopy if it is ASC-US or more. If cytology is normal
women are re-invited for newHPV testing after 12months and referred
to colposcopy if still positive. If the newHPV test is negative they are re-
invited for a new screening round in 5 years.
The introduction of HPV-based screening in routine activity is starting
at different times in different regions. In addition, in order to avoid too
large variations in workload due to the interval change, all regions invite
an increasing proportion of eligible women for HPV, reaching 100% not
before 3 years. In 2015 HPV-based screening was proposed to 16.0% of
the women invited for cervical screening in Italy. Some 50.1% of them ac-
cepted (www.osservatorionazionalescreening.it).
In addition to the organised programs, there is spontaneous screening.
The national survey PASSI reports that, during the 2011–14 period, 78.7%
of women aged 25 to 64 years reported having undergone a Pap test (or
an HPV test) during the past 3 years. Slightly more than half stated they
haddone this inpublic facilities, free of chargewithin screeningprograms.
This proportion had increased since active surveillance began (in 2008)
(CNESPS and ISS, 2015a). There are howevermarkeddifferences in invita-
tional coverage, participation and opportunistic activity between Italian
regions (ONS, 2015; CNESPS and ISS, 2015a).
3.1.2. Risk of CIN3 and cancer by HPV type: main cohort studies review
The non-systematic review of the 4 cohorts showed that, for women
with infection by HPV16, the risk of CIN3+ is 2.1 to 8.1 fold that of
women with infections by non-16/18 HPV types (Khan et al., 2005;
Castle et al., 2009; Kjær et al., 2010; Schiffman et al., 2011; Thomsen
et al., 2015). The risk for women with infection by HPV18 is 1 to 4.4
fold that of women with infection by non-16/18 HPV types. Infection
from HPV16 or HPV18 or HPV45 is associated with a younger median
age at onset, resulting in a higher proportion of HPV16/18- positive can-
cers among youngerwomen (Giorgi Rossi et al., 2012a; de Sanjose et al.,
2010; Carozzi et al., 2010; de Sanjose et al., 2011).
3.1.3. Immunogenicity duration: systematic review
The systematic review, based on 13 studies, concluded that, for the
bivalent vaccine, immunogenicity and protection against infections
and CIN2+ attributable to HPV16 or 18 lasted at least 9.4 years (Villa
et al., 2006; Olsson et al., 2007; Harper, 2008; GlaxoSmithKline
Vaccine HPV-007 Study Group et al., 2009; De Carvalho et al., 2010; Lu
et al., 2011; Romanowski, 2011; Roteli-Martins et al., 2012; Luna et al.,
2013; Naud et al., 2014; Ferris et al., 2014; Deleré et al., 2014; Schwarz
et al., 2015).
For the quadrivalent vaccine a follow up of 8 years was available,
during which a sustained antibody response to HPV16 was proven
(Ferris et al., 2014). Over the same period, the GMT titer for HPV 18
was 27 to 34 fold lower than the one reached at the 7th month, with aplateau from the 18th to the 72nd month. It is not possible to define
the efficacy due to lack of an 8-year control group. Anyway, no HPV 6/
11/16/18 related lesion nor infection persisting for ≥12months was re-
ported in the women vaccinated at the beginning of the study.
3.1.4. Vaccine population effectiveness: systematic review
The 20 studies selected in the review byDrolet et al. report follow up
data for N140 million person-years (Drolet et al., 2015; Tabrizi et al.,
2012; Australian Institute of Health and Welfare, 2013; Sandø et al.,
2014; Chow et al., 2015; Brotherton et al., 2015). In countries where a
vaccination coverage ≥50% was reached in girls aged 13 to 19 years, in-
fections by HPV 16/18 were 68% (RR 0.32, 95%CI 0.19–0.52) lower after
vaccination than before. A lower reduction of infections by HPV 31, 33
and 45 (RR 0.72 95%CI 0.54–0.96) was observed, which suggests
cross-protection. A significant drop in anogenital warts was also ob-
served in adolescents below age 20 (RR 0.66 95%CI 0.47–0.91) and in
women aged 20–39 years (RR 0.68 95%CI 0.51–0.89). This suggests a
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coverage was b50% significant reductions in infections from HPV 16/
18 (RR 0.50 95%CI 0.34–0.74) have been observed in girls under the
age of 20, without any evidence of cross-protection or herd effect.
More recent studies confirm the effectiveness of vaccines (Kavanagh
et al., 2014; Pollock et al., 2014; Baldur-Felskov et al., 2014). Pollock et
al. observed a reduction in CIN1 (RR 0.71, 95%CI 0.58–0.87; p =
0.0008), CIN2 (RR 0.5, 95%CI 0.40–0.63; p = 0.0001) and CIN3 (RR
0.45, 95%CI 0.35–0.58; p = 0.0001) in vaccinated women aged 20–21
compared to those who had not been vaccinated. Baldur-Felskov et al.
observed a 33.4% reduction of positive cytologies among girls aged
b18 years and 12.6% among girls aged 18–20 years (Pollock et al.,
2014; Baldur-Felskov et al., 2014).
3.1.5. Cross-protection and type replacement
Some cross-protection by bivalent and quadrivalent vaccines to-
wards different non-16/18 HPV genotypes emerged from the systemat-
ic review on effectiveness. There is not yet sufficient evidence on the
duration of such protection (Lipsitch, 1999; Palmroth et al., 2012;
Lehtinen and Dillner, 2013; Joura et al., 2015; Kreimer et al., 2015).
The concept of type replacement denotes two different phenomena,
one related to competition for the ecological niche and one connected
with the presence of competitive risks. If there was ecological competi-
tion between different HPV genotypes, the long-term effectiveness of
the vaccination would be reduced due to the increase in infections by
non-16/18 types. This phenomenon would imply a negative association
between infections with different genotypes, a phenomenon that was
never observed in many cross-sectional studies (Carozzi et al., 2010).
As for competitive risks, it is actually plausible that, in case of co-pres-
ence of lesions due to different genotypes, those that progressmore rap-
idly to invasive cancer (like those due to HPV16/18) may prevent the
onset of cancers due to the other genotype(s) infections. This can hap-
pen either because during treatment the lesion which has not yet
progressed is also removed or, less frequently, because the first cancer
causes death before the second lesion progresses to invasion. It is there-
fore reasonable to expect that in a vaccinated population the occurrence
of lesions and cancers attributable to non-vaccine HPV will increase.
3.2 Question 2. - If so, which policy appears to be the most effectively and
operatively manageable? Tailored or one size fits all?
3.2.1. Vaccine coverage in Italy
In Italy vaccine coverage does not reach the 95% objective, which is
traditionally used for vaccine coverage for common childhood diseases,
such as measles. The national coverage in cohorts of 12-year-old girls is
71%, with regions that do not reach 50% (Giambi, 2014; Giambi et al.,
2013; Intesa tra il Governo, le Regioni e le Province autonome di
Trento e Bolzano, 2015). The recommended schedule is currently 2
doses for the 12 years old girls (Dobson et al., 2013; CSS, 2015).
3.2.2. Vaccination strategies in Italy
Vaccination was extended to cohorts of 16-, 18- or 25-year old
women only in some regions. Coverage was lower than in 12-year old
girls (Intesa tra il Governo le Regioni e le Provincie autonome.
Strategie per l'offerta attiva del vaccino contro l'infezione da HPV in
Italia, 2007; CNESPS, ISS, 2015b). These coverage levels are borderline
for resulting in a herd immunity effect, i.e. in a reduction of infection
and cancer risk among unvaccinated women (Drolet et al., 2015).
3.2.3. Italian cancer registries: trends and pre-screening incidence
AIRTUM, the association of Italian cancer registries, estimated 2135
new invasive cervical cancers nationwide during 2014. Of them 35 are
expected in the 25–29 age range and 125 in the 20–34 age range
(AIRTUM, 2015). Before organised screening (1990 to 1998), there
were 190 cases between 20 and 34 years of age (Fig. 2).Between 2006 and 2009, 5 deaths from cervical cancer were record-
ed in women aged 20 to 34 years. Time trends of ICC incidence rates
show an increase, although ICCs remain very rare, in women below
30 years old. This is plausibly, related to increased occurrence of HPV in-
fection in younger cohorts, because of changing sexual habits. In the 30–
34 year age range the time trend is decreasing.
3.3 Question 2.1. - At what age should screening start?
3.3.1. Systematic review and pooled analysis of typing studies in Italy
The systematic reviews conducted by IARC show an increasing pro-
portion of HPV16 and 18 with increasing grade of CIN and in ICC. The
proportion of ICC attributable to HPV16 is higher in Europe than in
some other continents (Clifford et al., 2003a; Clifford et al., 2003b;
Smith et al., 2007; Guan et al., 2012; Guan et al., 2013). These results
are in agreement with those of the review of cohort studies about pro-
gression times. It is less clear whether the proportion of HPV16 and 18
among all invasive cancers increases over time. This is because ICC
time trends are compressed by increases in screening effectiveness
and because of changing in typing accuracy (Li et al., 2011).
In the systematic review by ICO 25 Italian studies were included, 11
related to CIN3 and 14 to ICC, reaching a total of 2354 CIN3 and 1308 ICC
genotyped (Bruni et al., 2015; Carozzi et al., 2010; Laconi et al., 2000;
Zerbini et al., 2001; Tornesello et al., 2006; Gargiulo et al., 2007; Capra
et al., 2008; Venturoli et al., 2008; Agarossi et al., 2009; Sandri et al.,
2009; Giorgi Rossi et al., 2010; Spinillo et al., 2014; Garzetti et al.,
1998; Voglino et al., 2000; Ciotti et al., 2006; Del Mistro et al., 2006;
Lillo et al., 2008; Rolla et al., 2009; Sideri et al., 2009; Mariani et al.,
2010; Tornesello et al., 2011).
The pooled analysis performed on 723 typed Italian ICC confirmed
an increased frequency of HPV16 and 18 in younger women and in-
creasing time trends, both for squamous cell carcinomas and for the
other histological types (Carozzi et al., 2010; Tornesello et al., 2006;
Gargiulo et al., 2007; Spinillo et al., 2014; Del Mistro et al., 2006; Lillo
et al., 2008; Sideri et al., 2009; Mariani et al., 2010; Tornesello et al.,
2011; Giorgi Rossi et al., 2012a).
3.3.2. Estimated cancer incidence under different scenarios of age to start
The number of cancers not prevented when increasing the age to
start screening up to 30 years for vaccinated girls changed according
to how the proportion of non-16/18 ICC was estimated ((a) raw, (b)
frommodel with linear age effect or (c) frommodel with age in classes,
see Methods). It was 5 ICC cases with approach (a), 10.5 ICC cases with
approach (b) and 5.5 ICC caseswith approach (c). By comparison, about
8 ICC cases cannot be prevented by screening programs each year na-
tionwide because they occur at age b 25 (Commissione Oncologica
Nazionale, 1996). When increasing the age of start of screening to
35 years un-prevented cancers would be 19 ICC cases with approach
(a) 43 ICC cases with approach (b) and 49 ICC cases with approach (c).
3.4 Question 2.2. – With which test?
3.4.1. Impact of vaccine on Pap test accuracy
There is general agreement that in vaccinated women cytology will
have a substantially lower positive predictive value (PPV) for CIN2+
than in the current situation. This will be due on one hand to the strong
reduction in prevalence of CIN2+ among vaccinated women, depend-
ing on the lower prevalence of infections by high-risk HPV types and
on the lower risk of progression to CIN2+ of infections from non-
HPV16/18 genotypes (Giorgi Rossi et al., 2012b). On the other hand,
false positive cytological abnormalities caused by low risk HPV infec-
tions or other conditions will still be present. Thus, the probability that
cytological abnormalities correspond to a CIN2+, i.e. PPV, is expected
to strongly decrease. The low prevalence of lesions could also reduce
the ability of cytologists to recognize them, thus the sensitivity of cytol-
ogy (Pollock et al., 2014; Franco et al., 2009; Tota et al., 2010). This is not
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will concentrate in HPV-positive women (Franco et al., 2009; Castle et
al., 2011).
Were the age to start screening in Italy increased up to 30 years, then
all women would be screened by HPV, which is already recommended
in the general population from this age upwards (Ronco et al., 2012;
von Karsa et al., 2015).
For the screening of a vaccinated population, it would also be appro-
priate to use tests that allow detecting the vaccine HPV types. This
would also permit a more accurate assessment of the population effec-
tiveness of vaccination. Affordable tests that combine the search for
hrHPV types with HPV16 and HPV18 partial typing are already on the
market.
With current guidelines, in Italy, non-vaccinated women would
have cytology-based screening from 25 to 30/34 years of age and
HPV-based screening thereafter.
3.5 Question 2.3. – With which interval?
To the moment there is a strong rational to state that screening in-
tervals longer than the current ones will be safe in vaccinated women
but there is not sufficient evidence to define their optimal length. In
order to obtain early information the screening results at age 30 in the
women vaccinated in their 16th year or later can be crucial. These
women are not strictly comparable to those screened at 12 because of
a greater probability of being already infected when vaccinated but
those negative for HPV16 and 18 at age 25 either were not infected at
vaccination or have cleared infection. In principle the ICC cumulative in-
cidence after a negative test is the parameter of reference to define
screening intervals. However, given the rarity of ICC, especially at
young age, CIN3+ can be used as a surrogate, also because its preva-
lence is a strong determinant of screening efficiency. Thus, it can be cho-
sen to apply a longer interval (e.g. 1 year) if the detection rate of CIN3+
at age 30 is lower than a reference value. This process can be repeated
with further birth cohorts in order to accept longer intervals. In the
NTCC trial, amongwomen aged 25–34 years at enrolment, the detection
of CIN3+ at the second screening round with cytology, after 3 years,
was 1.5 per 1000. This represents the value implicitly accepted with cy-
tology-based screening. A 1/1000 DR (33% lower) after a longer (≥5-
years) interval can plausibly be considered as safe for moving to a 1-
year longer interval.
Certainly, the residual disease threshold is age dependent and a
threshold defined in young women cannot be extended to older
womenwhere the prevalence of CIN3 is lower but their risk of progres-
sion to cancer is higher. Therefore, as a safety check, vaccinated women
screened with prolonged intervals will be followed-up and their detec-
tion rate compared to that observed in unvaccinated women of same
age screened by HPV (see research recommendations and Fig. 3).
3.6 Question 3. - Should the strategy be diversified for the cohorts vaccinat-
ed in their fifteenth year (or later) with respect to those vaccinated in their
twelfth year?
The vaccine strategies of regions have sometimes included addition-
al cohorts of 16, 18 and 25-year old women. The Pregio study estimated
a median age for first sexual intercourse in Italy of 17 years, without
substantial differences between geographical areas (Donati et al.,
2012). Therefore, it can be assumed that less than half of the girls vacci-
nated in their 16th year and more than half of those vaccinated subse-
quently have already had sexual intercourse and therefore may not be
HPV-naive at vaccination. Vaccine is not effective on infection clearance
(The FUTURE II Study Group, 2007; Paavonen et al., 2007).
At the same time, data on occurrence of infections and lesions in
these cohorts collected by screening programs could be fundamental
for filling the gaps in knowledge, providing useful elements forchanging the screening program for girls vaccinated in their twelfth
year. Thus, these cohorts should still be screened at age 25.
3.7. Question 4-What actions need to be scheduled between now and 2021
to acquire missing evidence and make the integration of primary and sec-
ondary prevention practically possible?
4. Recommendations for the reorganisation of cervical cancer
screening
Screening must be re-organised from 2021 and the first changes
must already be arranged.
For girls vaccinated in their twelfth year (±1 year), i.e. at an age in
which the probability of already having had sexual intercourse is very
low, a combined sequential strategy is proposed:
A. A tailored strategy, which involves the availability of a link between
vaccination registers and screening programs. In this way, both girls
vaccinated in their twelfth year and screening programs can count
on a better cost-efficacy ratio;
B. A uniform strategy,which can be adoptedwhen theRegional or local
coverage data have reached the threshold, which should be defined
on the basis of the population effectiveness (including the herd ef-
fect) of the HPV vaccine in Italy and in the other countries where
monitoring is in progress. With this approach, the Regions that
reach the objective will have a greater advantage with respect to
the tailored screening strategy in terms of lower system complexity.
Vaccination coverage is an indicator that may change over time and
not be uniform within the same Region. This variability must also be
considered. The minimum coverage threshold may be subject to future
assessment according to an improved understanding of the resulting
protection, also for non-vaccinated subjects, due to herd immunity.
This would also improve substantially through the possible extension
of vaccination to Italian adolescent males. Screening and vaccination
servicesmust be coordinated and the respective staffmust be adequate-
ly trained on the rationale of the new protocols.
With a screening starting age delayed to 30 years, women vaccinat-
ed in their 12th year would start screening at an age in which in Italy
and in Europe the HPV test is already recommended as a primary test.
It is likely that the interval between screening tests will be extended,
but this possibility must be assessed with a research project, in order to
guarantee optimal protection with the lowest possible number of tests.
Compared to the 14 screening episodes envisaged with traditional
cytological screening, women with HPV screening will undergo, over
40 years of life, to up 9 screening episodes if they are not vaccinated
and even less if they are vaccinated. Therefore, extending the current in-
terval between screening from three to five years, delaying the start of
the program to the age of 30 for women vaccinated in their 12th year,
and the possible further extension of intervals for vaccinated women -
based on the evidence acquired in the meantime - will lead to a change
and to a progressive reduction in the workloads of screening programs
(coordinating centres, first-level clinics, laboratories, pathology and
gynecology units). This will increase the sustainability of the programs
over time and lead to a more efficient use of resources.
The proposals to change protocols as per the previous questions are
applicable to the cohorts of girls vaccinated in their 12th year. In the co-
horts vaccinated in their fifteenth year or later, screening will still start
at age 25 with the Pap test.
5. Recommendations for implementation and research
The jury fully accepted the proposals for the implementation and re-
search of the Scientific Technical Committee (see Table 3). In fact, it sup-
ported with full consent the need to launch programmatic monitoring
Fig. 3. Study design and sample size estimation for gradually extending the screening interval in vaccinated and HPV-negative women.
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nation registers, screening registers and cancer registers, for which cen-
tral planning and support interventions are required.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ypmed.2016.11.020.
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